Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE (PREVALUNG*)

Inclusion Criteria: Age 45- 75 years and Medical follow-up for a smoking-related pathology : atheroma chronic obstructive pulmonary disease / emphysema history of non evolving cancer > 5 years among: ENT, lung, breast, cervical, excreto-urinary cervix, excreto-urinary tract, bladder, esophagus, stomach, pancreas, liver, kidney, chronic myeloid leukemia chronic myeloid leukemia, daily smoking for at least 10 years prior to the disease Or NLST inclusion criteria: Age 55 - 74 years Cumulative smoking ≥ 30 pack-years active or quit for less than 15 years Or Inclusion criterion in NELSON: Age 50-75 years Smoking: > 15 cigarettes/D for more than 25 years or > 10 cigarettes /D for more than 30 years Active smoking or cessation < 10 years Or New American recommendations : Age 50 - 80 years Smoking ≥20 PA Active or weaned <15 years Exclusion Criteria: history of cancer < 5 years (except carcinoma in situ of the uterine cervix, basal cell skin carcinoma basal cell carcinoma of the skin and prostate cancer with undetectable PSA) Symptoms of lung cancer (unintentional weight loss > 7 kg in 1 year, hemoptysis) known history of pulmonary nodule with specialized follow-up history of pulmonary fibrosis or pulmonary hypertension patient under guardianship or curatorship active pulmonary parenchymal infection severe cardiac or respiratory insufficiency (rest dyspnea) patient not affiliated to the social security system (beneficiary or beneficiary's right) Patient deprived of liberty Performance status (WHO) 2, 3 or 4 Pregnant or breastfeeding women